Gene: MYLIP

29116
IDOL|MIR
myosin regulatory light chain interacting protein
protein-coding
6p22.3
Ensembl:ENSG00000007944 MIM:610082 Vega:OTTHUMG00000016405 UniprotKB:Q8WY64
NC_000006.12
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.280e-1 (AD)  4.711e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TCP10.805
ZNF1310.804
TLK20.803
RYBP0.8
MTDH0.787
USPL10.784
TARS0.784
ARCN10.778
KANSL20.776
BIRC20.775

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.498
OR4F29-0.482
ALDH1L1-AS2-0.268
GLI1-0.266
RNF43-0.257
PON1-0.25
PON3-0.242
STON2-0.236
SLC2A4-0.231
PHEX-0.225

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C00358522-hydroxycholesterol22-hydroxycholesterol results in increased expression of MYLIP mRNA22156476
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYLIP mRNA"19167446
C07699627-hydroxycholesterol27-hydroxycholesterol results in increased expression of MYLIP mRNA22156476
D0000737382-Hydroxypropyl-beta-cyclodextrin2-Hydroxypropyl-beta-cyclodextrin results in decreased expression of MYLIP mRNA22156476
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of MYLIP mRNA21420995|2906747
D020106AcrylamideAcrylamide results in decreased expression of MYLIP mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MYLIP gene27153756
C519728archazolid Barchazolid B results in decreased expression of MYLIP mRNA25218289
D001151ArsenicMYLIP mRNA results in decreased susceptibility to Arsenic17976673
D001280AtrazineAtrazine results in increased expression of MYLIP mRNA25929836
D001280AtrazineAtrazine results in increased expression of MYLIP mRNA22378314
C487081belinostatbelinostat results in increased expression of MYLIP mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MYLIP mRNA20064835|2180250
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MYLIP mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MYLIP mRNA"20018196
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of MYLIP mRNA"20382639
D004958EstradiolEstradiol results in decreased expression of MYLIP mRNA19167446
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in decreased expression of MYLIP mRNA25270620
C044887beta-methylcholinebeta-methylcholine affects the expression of MYLIP mRNA21179406
C006780bisphenol Abisphenol A affects the expression of MYLIP mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MYLIP gene28505145
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYLIP mRNA22079614
C584509C646 compoundC646 compound results in increased expression of MYLIP mRNA26191083
D002104CadmiumCadmium results in increased expression of MYLIP mRNA21120746
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of MYLIP mRNA25270620
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in increased expression of MYLIP mRNA26272509
C100187chloropicrinchloropicrin results in increased expression of MYLIP mRNA26352163
D002922CiguatoxinsCiguatoxins affects the expression of MYLIP mRNA18353800
D003300Copper[Disulfiram binds to Copper] which results in decreased expression of MYLIP mRNA24690739
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of MYLIP mRNA20971185
D019327Copper SulfateCopper Sulfate results in increased expression of MYLIP mRNA19549813
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYLIP mRNA"19167446
D003375CoumestrolCoumestrol results in decreased expression of MYLIP mRNA19167446
D003471CuprizoneCuprizone results in decreased expression of MYLIP mRNA26577399
D016572CyclosporineCyclosporine results in increased expression of MYLIP mRNA25562108
D003561CytarabineCytarabine results in decreased expression of MYLIP mRNA21198554
D004041Dietary FatsDietary Fats results in decreased expression of MYLIP mRNA18042831
D002117CalcitriolCalcitriol results in decreased expression of MYLIP mRNA16002434
D004221Disulfiram[Disulfiram binds to Copper] which results in decreased expression of MYLIP mRNA24690739
D004317DoxorubicinDoxorubicin results in increased expression of MYLIP mRNA25896364
C118739entinostatentinostat results in increased expression of MYLIP mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYLIP mRNA22079256
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of MYLIP mRNA23649840
D005472FluorouracilFluorouracil affects the expression of MYLIP mRNA16584549
D005557FormaldehydeFormaldehyde results in increased expression of MYLIP mRNA20655997|2364984
C039281furanfuran results in increased expression of MYLIP mRNA27387713
D019833GenisteinGenistein results in increased expression of MYLIP mRNA18847459
D005839GentamicinsGentamicins results in increased expression of MYLIP mRNA22061828
D006534Heptachlor EpoxideHeptachlor Epoxide results in decreased expression of MYLIP mRNA25270620
C475919hydroxytamoxifenhydroxytamoxifen results in decreased expression of MYLIP mRNA16849584
C492448ICG 001ICG 001 results in increased expression of MYLIP mRNA26191083
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MYLIP mRNA25613284
D007545IsoproterenolIsoproterenol results in increased expression of MYLIP mRNA20003209
C544151jinfukangjinfukang results in decreased expression of MYLIP mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of MYLIP mRNA23086925
D007854LeadLead affects the expression of MYLIP mRNA22313790|2890349
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of MYLIP mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of MYLIP mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of MYLIP mRNA"26251327
D008777MethyltestosteroneMethyltestosterone results in increased expression of MYLIP mRNA29191790
D015735MifepristoneMifepristone results in decreased expression of MYLIP mRNA25972201
D016685MitomycinMYLIP protein affects the susceptibility to Mitomycin16217747
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of MYLIP mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MYLIP mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of MYLIP mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MYLIP mRNA"25620056
C029938nickel sulfatenickel sulfate results in increased expression of MYLIP mRNA22714537
C570897NSC668394NSC668394 results in decreased expression of MYLIP mRNA27137931
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of MYLIP mRNA20971185
D015525Fatty Acids, Omega-3"Fatty Acids, Omega-3 results in decreased expression of MYLIP mRNA"23333450
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 gene polymorphism affects the susceptibility to [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of MYLIP mRNA]"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of MYLIP mRNA"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 protein affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of MYLIP mRNA]"21673326
D000073878Palm OilPalm Oil results in decreased expression of MYLIP mRNA18042831
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of MYLIP mRNA26272509
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of MYLIP mRNA18593933
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of MYLIP mRNA19162173
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in decreased expression of MYLIP mRNA]19482888
D010634PhenobarbitalPhenobarbital affects the expression of MYLIP mRNA23091169
D010634PhenobarbitalPhenobarbital results in decreased expression of MYLIP mRNA19482888
D010938Plant OilsPlant Oils results in increased expression of MYLIP mRNA23370395
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYLIP mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of MYLIP mRNA22079256|2271453
D011374ProgesteroneProgesterone results in decreased expression of MYLIP mRNA21795739
D011374ProgesteroneProgesterone results in increased expression of MYLIP mRNA18037150
D011794QuercetinQuercetin results in increased expression of MYLIP mRNA21632981
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of MYLIP mRNA21427059
D012715Sesame OilSesame Oil results in decreased expression of MYLIP mRNA29191790
C016104sodium bichromatesodium bichromate results in increased expression of MYLIP mRNA17685462
D012999SomanSoman results in increased expression of MYLIP mRNA19281266
D053260SootSoot results in decreased expression of MYLIP mRNA22461453
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of MYLIP mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of MYLIP mRNA21802500
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of MYLIP mRNA25975270
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MYLIP mRNA22298810
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MYLIP mRNA25613284
C423915TO-901317TO-901317 results in increased expression of MYLIP mRNA22156476
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of MYLIP mRNA28065790
D014212TretinoinTretinoin results in increased expression of MYLIP mRNA20530235
D014212TretinoinTretinoin results in increased expression of MYLIP mRNA21934132
D014212TretinoinTretinoin results in decreased expression of MYLIP mRNA20488242
D014241TrichloroethyleneTrichloroethylene results in increased methylation of MYLIP gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of MYLIP mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of MYLIP mRNA"24407104
D014415TunicamycinTunicamycin results in decreased expression of MYLIP mRNA22378314
D014520UrethaneUrethane results in increased expression of MYLIP mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYLIP mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of MYLIP mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of MYLIP mRNA17292431
D014635Valproic AcidValproic Acid results in increased expression of MYLIP mRNA19136453|2142705
D001335Vehicle EmissionsVehicle Emissions results in increased expression of MYLIP mRNA19465080
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of MYLIP mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004842ubiquitin-protein transferase activity-EXP19028597  
GO:0004842ubiquitin-protein transferase activity-IBA21873635  
GO:0004842ubiquitin-protein transferase activity-IDA14550572  
GO:0004842ubiquitin-protein transferase activity-TAS-  
GO:0005515protein binding-IPI12826659  25416956  
GO:0008092cytoskeletal protein binding-IDA10593918  
GO:0046872metal ion binding-IEA-  
GO:0061630ubiquitin protein ligase activity-IDA21685362  
GO:0061630ubiquitin protein ligase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000209protein polyubiquitination-TAS-  
GO:0006511ubiquitin-dependent protein catabolic process-IEA-  
GO:0007399nervous system development-IMP10593918  
GO:0010977negative regulation of neuron projection development-IMP10593918  
GO:0010989negative regulation of low-density lipoprotein particle clearance-IEA-  
GO:0016567protein ubiquitination-IDA14550572  
GO:0031032actomyosin structure organization-IBA21873635  
GO:0031648protein destabilization-IEA-  
GO:0032802low-density lipoprotein particle receptor catabolic process-TAS-  
GO:0032803regulation of low-density lipoprotein particle receptor catabolic process-IEA-  
GO:0042632cholesterol homeostasis-IEA-  
GO:0045732positive regulation of protein catabolic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005622intracellular-IDA10593918  
GO:0005829cytosol-TAS-  
GO:0005856cytoskeleton-IBA21873635  
GO:0005886plasma membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-174824Plasma lipoprotein assembly, remodeling, and clearanceTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-8866427VLDLR internalisation and degradationTAS
R-HSA-8964043Plasma lipoprotein clearanceTAS
R-HSA-983168Antigen processing: Ubiquitination & Proteasome degradationTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23107276Association of MYLIP rs3757354 SNP and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations. (2012 Oct 29)Yan TTLipids Health Dis